A Palo Alto-based company, Greenstone Biosciences, Inc., has revealed a partnership with Intel Corp. (NASDAQ: INTC) to enhance AI-driven drug discovery. This collaboration aims to leverage Greenstone's extensive human biobank of induced pluripotent stem cells in conjunction with Intel's Edge AI advanced computing and AI infrastructure. The joint effort seeks to expedite the process of creating novel medications. By merging cutting-edge human genetics and biology expertise from Greenstone with Intel's advanced technology solutions, the initiative aims to revolutionize the field of drug discovery.